Dr James C Delehanty, MD | |
16 Fahey St, Suite 208 Cobb Med. Bldg, Belfast, ME 04915-6029 | |
(207) 338-1728 | |
(207) 338-5661 |
Full Name | Dr James C Delehanty |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Experience | 49 Years |
Location | 16 Fahey St, Belfast, Maine |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1184662439 | NPI | - | NPPES |
007018 | Other | ME | ANTHEM |
2278089 | Other | ME | AETNA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | 009407 (Maine) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Waldo County General Hospital | Belfast, ME | Hospital |
Mailing Address | Practice Location Address |
---|---|
Dr James C Delehanty, MD 16 Fahey St, Suite 208 Cobb Med. Bldg, Belfast, ME 04915-6029 Ph: (207) 338-1728 | Dr James C Delehanty, MD 16 Fahey St, Suite 208 Cobb Med. Bldg, Belfast, ME 04915-6029 Ph: (207) 338-1728 |
News Archive
A report released last week by the Presidential Commission for the Study of Bioethical Issues examining federally sponsored research involving human volunteers, called "Moral Science: Protecting Participants in Human Subjects Research," said that "current rules and regulations provide adequate safeguards to mitigate risk," "recommended 14 changes to current practices to better protect research subjects, and called on the federal government to improve its tracking of research programs supported with taxpayer dollars," according to a Commission press release.
Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.
People with a particular gene variant may be more likely to develop brain tumors, and at an earlier age, than people without the gene, according to a study published in the January 27, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.
Merck Sharp & Dohme Ltd. MSD (known as Merck & Co., Inc. in the United States and Canada), today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection.
› Verified 4 days ago
Demetrius Peter Rizos, DO Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 125 Northport Ave, Belfast, ME 04915 Phone: 207-661-2018 | |
Alicia Snow, NP-C Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 16 Fahy St, Belfast, ME 04915 Phone: 207-338-5440 | |
Kenneth Temple Calamia, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 126 Northport Ave, Suite 106, Belfast, ME 04915 Phone: 207-505-4015 | |
Faisal Jamal, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 116 Northport Ave, Belfast, ME 04915 Phone: 207-505-4080 | |
Dr. Akavaram N Reddy, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 116 Northport Ave Ste 220, Belfast, ME 04915 Phone: 207-505-4015 Fax: 207-338-8368 | |
Mauricio Botero-velez, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 16 Fahy St, Belfast, ME 04915 Phone: 207-505-4304 |